NDA 019887 · Fresenius Kabi USA
Nebupent
Pentamidine Isethionate · Inhalation
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: Feb 16, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1989
Jun 15, 1989
Approved uses
2
Original approval plus efficacy supplements
Registered trials
48
13 Phase 3, 2 recruiting
FAERS reports
1,217
1,086 serious, 217 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 15, 2024.
INDICATIONS AND USAGE: NebuPent is indicated for the prevention of Pneumocystis jiroveci pneumonia (PJP) in high-risk, HIV-infected patients defined by one or both of the following criteria: i. a history of one or more episodes of PJP ii. a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm 3 . These indications are based on the results of an 18-month randomized, dose-response trial in high risk HIV-infected patients and on existing epidemiological data from natural history studies. The patient population of the controlled trial consisted of 408 patients, 237 of whom had a history of one or more episodes of PJP. The remaining patients without a history of PJP included 55 patients with Kaposi’s sarcoma and 116 patients with other AIDS diagnoses, ARC or asymptomatic HIV infection. Patients were randomly assigned to receive NebuPent via the Respirgard ® II nebulizer at one of the following three doses: 30 mg every two weeks (n=135), 150 mg every two weeks (n=134) or 300 mg every four weeks (n=139). The results of the trial demonstrated a significant protective effect (p<0.01) against PJP with the 300 mg every four week dosage regimen compared to the 30 mg every two week dosage regimen. The 300 mg dose regimen reduced the risk of developing PJP by 50 to 70% compared to the 30 mg regimen. A total of 293 patients (72% of all patients) also received zidovudine at sometime during the trial. The analysis of the data demonstrated the efficacy of the 300 mg dose even after adjusting for the effect of zidovudine. The results of the trial further demonstrate that the dose and frequency of dosing are important to the efficacy of NebuPent prophylaxis in that multiple analyses consistently demonstrated a trend toward greater efficacy with 300 mg every...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 5, 1996 Supplement 2 · Efficacy
- Jun 15, 1989 Original approval · Type 3 - New Dosage Form · priority review
2 products under this application
- NEBUPENT · PENTAMIDINE ISETHIONATE 600MG/VIAL · FOR SOLUTION, INHALATION · Discontinued
- NEBUPENT · PENTAMIDINE ISETHIONATE 300MG/VIAL · FOR SOLUTION, INHALATION · Prescription · TE AN
Clinical trials
Interventional ClinicalTrials.gov studies with "Pentamidine Isethionate" as an intervention, any sponsor and status, largest first.
- Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)Pivotal-lookingNot yet recruiting
Institute of Tropical Medicine, BelgiumAcademic, hospital or other
NCT07463040 · 900 participants (planned) · Start Jan 1, 2027 · Primary completion Mar 1, 2029
Drug: Sodium Stibogluconate (SSG); Miltefosine and 3 more · For: Cutaneous Leihmaniasis
Sites: Addis Ababa, Ethiopia; Arba Minch, Ethiopia; Boru, Ethiopia
- A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMXPivotal-lookingCompleted
Glaxo WellcomeGSK (GSK)
NCT00002340 · 615 participants
Drug: Atovaquone; Pentamidine isethionate · For: Pneumonia, Pneumocystis Carinii; HIV Infections
Sites: Maitland, Florida; Tampa, Florida; New York, New York · 5 sites in all
- A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected PatientsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000991 · 600 participants
Drug: Pentamidine isethionate; Sulfamethoxazole-Trimethoprim and 2 more · For: Pneumonia, Pneumocystis Carinii; HIV Infections
Sites: Los Angeles, California; Oakland, California; San Diego, California · 21 sites in all
- A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07917754 · 470 participants (planned) · Start Dec 13, 2026 · Primary completion Mar 13, 2037
Drug: MK-1045; Zilovertamab vedotin and 8 more · For: Lymphoma, Large B-Cell, Diffuse; Diffuse Large B-Cell Lymphoma
- Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)Pivotal-lookingNot yet recruiting
McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
NCT07357103 · 416 participants (planned) · Start Mar 2026 · Primary completion Mar 2029
Drug: Clindamycin + primaquine; Pentamidine and 1 more · For: Pneumocystis; Pneumocystis Infection; Pneumocystis Carinii Infection and 5 more
- A Study of Pentamidine Plus Dapsone in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients Who Cannot Take Trimethoprim or SulfonamidesPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00001028 · 400 participants
Drug: Pentamidine isethionate; Dapsone · For: Pneumonia, Pneumocystis Carinii; HIV Infections
Sites: San Francisco, California; Denver, Colorado; Wilmington, Delaware · 14 sites in all
- Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDSPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00001013 · 364 participants
Drug: Trimetrexate glucuronate; Pentamidine isethionate and 2 more · For: Pneumonia, Pneumocystis Carinii; HIV Infections
Sites: Los Angeles, California; Washington D.C., District of Columbia; Miami, Florida · 23 sites in all
- A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000727 · 322 participants
Drug: Pentamidine isethionate; Pyrimethamine and 3 more · For: Pneumonia, Pneumocystis Carinii; HIV Infections
Sites: Los Angeles, California; San Diego, California; San Francisco, California · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- febrile neutropenia135
- pyrexia134
- off label use83
- diarrhoea79
- neutropenia78
- aplastic anaemia77
- pneumonia62
- sepsis58
- mucosal inflammation57
- pancytopenia53
- vomiting53
- nausea52
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 12 |
| 2005 | 20 |
| 2006 | 46 |
| 2007 | 46 |
| 2008 | 46 |
| 2009 | 67 |
| 2010 | 108 |
| 2011 | 66 |
| 2012 | 51 |
| 2013 | 27 |
| 2014 | 17 |
| 2015 | 27 |
| 2016 | 39 |
| 2017 | 37 |
| 2018 | 28 |
| 2019 | 56 |
| 2020 | 85 |
| 2021 | 93 |
| 2022 | 97 |
| 2023 | 49 |
| 2024 | 88 |
| 2025 | 72 |
| 2026 | 40 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Nebupent* (Pentamidine Isethionate*) · HCPCS J2545
2024 spending
$138K
Beneficiaries
486
1,802 claims
Per beneficiary
$284
2024 ASP limit $77.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $144,508 |
| 2021 | $150,087 |
| 2022 | $172,132 |
| 2023 | $158,306 |
| 2024 | $137,942 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of pentamidine isethionate for tegumentary and visceral human leishmaniasis: a systematic review.
Piccica M, Lagi F, Bartoloni A, et al. · J Travel Med 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Effect of antimicrobial and anti-inflammatory medications on the sense of taste.
Schiffman SS, Zervakis J, Westall HL, et al. · Physiol Behav 2000 · Clinical Trial, Controlled Clinical Trial
- Randomized single-blinded non-inferiority trial of 7 mg/kg pentamidine isethionate versus 4 mg/kg pentamidine isethionate for cutaneous leishmaniaisis in Suriname.
Hu RV, Straetemans M, Kent AD, et al. · PLoS Negl Trop Dis 2015 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia.
Hughes WT, Feldman S, Chaudhary SC, et al. · J Pediatr 1978 · Clinical Trial, Comparative Study
- Alveolar targeting of aerosol pentamidine. Toward a rational delivery system.
Simonds AK, Newman SP, Johnson MA, et al. · Am Rev Respir Dis 1990 · Clinical Trial, Controlled Clinical Trial
- Treatment of Pneumocystis carinii pneumonia: current status of the regimens of pentamidine isethionate and pyrimethamine-sulfadiazine.
Young RC, DeVita VT · Natl Cancer Inst Monogr 1976 · Clinical Trial, Comparative Study
Sponsor: Fresenius Kabi USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.